Pancreatic Cancer Research

ResearcherActive in the last 2 years

Fengjun Xiao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4743-6146; OpenAlex author ID A5035893717. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 4

  1. NUDT21 interacts with NDUFS2 to activate the PI3K/AKT pathway and promotes pancreatic cancer pathogenesis. Last author DOI 10.1007/s00432-023-05540-1↗
  2. PTPMT1 regulates mitochondrial death through the SLC25A6-NDUFS2 axis in pancreatic cancer cells. Last author PMID 37034225↗
  3. Protein tyrosine phosphatase 1 protects human pancreatic cancer from erastin-induced ferroptosis. First author DOI 10.1016/j.asjsur.2021.11.048↗
  4. Beclin1 inhibition promotes autophagy and decreases gemcitabine-induced apoptosis in Miapaca2 pancreatic cancer cells. Co-author DOI 10.1186/1475-2867-13-26↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiao-Dong Huang · 3 shared papers, 2022–2024 · strength 0.60
  2. Yang Sun · 1 shared paper, 2022 · strength 0.19
  3. Xian-Jie Shi · 1 shared paper, 2022 · strength 0.19
  4. Peng-Peng Ding · 1 shared paper, 2023 · strength 0.18
  5. Hua Wang · 1 shared paper, 2013 · strength 0.04
  6. Lisheng Wang · 1 shared paper, 2013 · strength 0.04
  7. Xiaoshu Li · 1 shared paper, 2013 · strength 0.04
  8. Xiaozhong Guo · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.